Performance of the new Roche Cobas AmpliPrep-Cobas TaqMan version 2.0 human immunodeficiency virus type 1 assay.

摘要

The Cobas TaqMan human immunodeficiency virus type 1 (HIV-1) assay (Roche Molecular Systems, Branchburg, NJ) technology combines the extraction of total nucleic acids on the Cobas AmpliPrep (CAP) with real-time PCR on the Cobas TaqMan analyzer (CTM), using hydrolysis probe technology (5, 6, 9). This technology replaces the CAP-Cobas Amplicor version 1.5 assay (CAP-CA) (gag) based on endpoint PCR, which is limited by its dynamic range, 400 to 750,000 copies/ml for the standard assay and 50 to 100,000 copies/ml for the ultrasensitive assay (1, 5, 6). The CAP-CTM HIV-1 v2.0 assay uses primers targeting both gag and long terminal repeat regions of the HIV genome and has a reportable range of 20 to 1.0E+7 HIV RNA copies/ml (8).